Theravance Biopharma, Inc. (TBPH)
16.30
+0.08
(+0.49%)
USD |
NASDAQ |
May 18, 12:19
Theravance Biopharma Research and Development Expense (Quarterly) : 5.448M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Viatris, Inc. | 245.20M |
| Relmada Therapeutics, Inc. | 8.088M |
| Indivior Pharmaceuticals, Inc. | 9.00M |
| Corcept Therapeutics, Inc. | 66.26M |
| Assertio Holdings, Inc. | 0.454M |